| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $46.2M | -15.7% |
| SG&A Expense | $37.7M | -22.9% |
| Operating Income | -$83.9M | +19.1% |
| Net Income | -$80.0M | +19.0% |
| EPS (Basic) | -$2.65 | +19.2% |
| EPS (Diluted) | -$2.65 | +19.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.9M | -5.7% |
| Short-term Investments | $41.1M | -55.5% |
| Current Assets | $45.8M | -53.0% |
| Total Assets | $45.8M | -53.0% |
| Current Liabilities | $10.3M | -15.6% |
| Total Liabilities | $10.3M | -15.6% |
| Stockholders' Equity | $35.5M | -58.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$51.8M | -0.2% |
| Investing Cash Flow | $51.6M | +2.2% |
| Financing Cash Flow | -$40K | +59.0% |